Contact
1020 Locust Street
Room 368
Philadelphia, PA 19107
Highlighted Publications
Magee MS, Kraft CL, Abraham TS, Baybutt TR, Marszalowicz GP, Li P, Waldman SA, Snook AE. GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity. Oncoimmunology. 2016;5:e1227897. PMID 27853651, PMCID PMC5087292
This paper shows that CAR-T cells targeting GUCY2C treat metastatic colorectal cancer without cause toxicity in GUCY2C-expressing tissues. PDF: Magee-2016-OncoImmunology
Snook AE, Magee MS, Schulz S, Waldman SA. Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy. Eur J Immunol. 2014;44:1956-66. PMID 24771148, PMCID PMC4107120
This paper shows that GUCY2C-specific self-tolerance is mediated by selective CD4+ T-cell tolerance which can be exploited to improve vaccine efficacy without impacting vaccine safety. PDF: Snook-2014-Eur J Immunol
Snook AE, Li P, Stafford BJ, Faul EJ, Huang L, Birbe RC, Bombonati A, Schulz S, Schnell MJ, Eisenlohr LC, Waldman SA. Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease. Cancer Res. 2009;69:3537-44. PMID 19351847, PMCID PMC2707278
This paper shows that GUCY2C vaccination safely induces antitumor immunity without autoimmunity. PDF: Snook-2009-Cancer Res
Snook AE, Stafford BJ, Li P, Tan G, Huang L, Birbe R, Schulz S, Schnell MJ, Thakur M, Rothstein JL, Eisenlohr LC, Waldman SA. Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity. J Natl Cancer Inst. 2008;100:950-61. PMID 18577748, PMCID PMC2749952
This paper demonstrates that GUCY2C is a potential cancer vaccine target. PDF: Snook-2008-J Natl Cancer Inst
Publications
- Dietary L-Tryptophan consumption determines the number of colonic regulatory T cells and susceptibility to colitis via GPR15
- IL-8 correlates with nonresponse to neoadjuvant nivolumab in HPV positive HNSCC via a potential extracellular vesicle miR-146a mediated mechanism
- Intestinal neuropod cell GUCY2C regulates visceral pain
- In vitro assays to evaluate CAR-T cell cytotoxicity
- Chimeric adenoviral (Ad5.F35) and listeria vector prime-boost immunization is safe and effective for cancer immunotherapy
- Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma
- Guanylyl cyclase C as a diagnostic and therapeutic target in colorectal cancer
- Immune checkpoint inhibitors in luminal gastrointestinal malignancies: Going beyond MSI-H/dMMR, TMB and PD-L1
- Functional Assessment of Missense Variants in the ABCC6 Gene Implicated in Pseudoxanthoma Elasticum, a Heritable Ectopic Mineralization Disorder
- T-Cell Responses to Immunodominant Listeria Epitopes Limit Vaccine-Directed Responses to the Colorectal Cancer Antigen, Guanylyl Cyclase C
- Guanylyl Cyclase Receptors
- The poorly immunogenic tumor microenvironment of pancreatic cancer: The impact of radiation therapy, and strategies targeting resistance
- Overview of predictive and prognostic biomarkers and their importance in developing a clinical pharmacology treatment plan in colorectal cancer patients
- A β-Catenin-TCF-Sensitive Locus Control Region Mediates GUCY2C Ligand Loss in Colorectal Cancer
- Emerging drug targets for colon cancer: A preclinical assessment
- Targeting gastrointestinal cancers with chimeric antigen receptor (CAR)-T cell therapy
- Genetic heterogeneity of heritable ectopic mineralization disorders in a large international cohort
- Evaluation of CAR-T cell cytotoxicity: Real-time impedance-based analysis
- Cancer vaccines and immunotherapy for tumor prevention and treatment
- Emerging targets for the diagnosis of Parkinson's disease: Examination of systemic biomarkers